GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

Pharmaceutical giant GlaxoSmithKline is sidestepping its pledge to lower asthma inhaler prices, a key senator charged Wednesday, in the latest effort by Democrats to pressure drug companies on the ...

U.S. Sen. Elizabeth Warren has slammed GSK (NYSE:GSK) for alleged price-gouging over the marketing of its pediatric asthma drug Flovent HFA and its authorized generic. In a statement released ...

GSK’s filing is supported by data from the phase 3 clinical study CAPTAIN, conducted in 2,436 adults with uncontrolled asthma across 15 countries, and positive headline results were reported in May.